Aratana Shared Insights on New Therapeutics in Development at Veterinary Orthopedic Society Conference

The Aratana CE dinner program was an informative evening for VOS attendees. On the evening of February 29 in Big Sky, Montana, conference attendees learned about new therapeutics in development for their patients from Aratana.

Veterinary guests found themselves at the intersection of human science and veterinary medicine, hearing information on clinical studies from Aratana for therapeutics anticipated to launch in 2016 and beyond. This CE-approved event included topics on post-operative pain, osteosarcoma and osteoarthritis. Presenters included:

  • Jessica Wofford, DVM, PhD, who discussed the unmet medical need for extended post-operative pain management in dogs and shared a summary of clinical studies from a bupivacaine liposome injectable suspension for pain relief in dogs following cranial cruciate ligament
  • Nicole Ehrhart, VMD, MS, DACVS, ACVS Founding Fellow, Surgical Oncology, who provided a look at the prevalence of canine osteosarcoma and the limitations of current treatment options on long-term survival. Her discussion highlighted investigational therapeutics, with specific emphasis on a Listeria-based therapeutic vaccine for osteosarcoma in dogs
  • Steven Fox, MS, DVM, MBA, PhD, discussed a potential novel therapeutic option for canine osteoarthritis, a PGE2 EP4 prostaglandin receptor antagonist (PRA) within the piprant class, grapiprant. Dr. Fox explained the mechanism of action and reviewed a summary of recent clinical studies
  • Recent clinical studies of an allogeneic stem cell therapy for osteoarthritis in dogs was presented by Scott Gustafson, DVM, MS, DACVS
  • Caleb Hudson, DVM, MS, DACVS-SA with Gulf Coast Veterinary Specialists in Houston provided attendees with a “State of the Industry” presentation on both current and future local anesthetics

View studies and observations relating to new therapeutics in development at

Recent News Posts

View All